GeneCentric’s mission is to become a leader in the development and commercialization of technology that defines cancer drug responder populations and thereby enhances success in drug development.
We partner with pharmaceutical and biotechnology companies to identify the most complete spectrum of responder populations to their drugs and drug candidates across throughout the e drug development process. The efficacy of our Cancer Subtype Platform (CSP®) in bringing insight and intelligence to the challenging realm of drug development can be seen at all stages – from discovery and translational research, to clinical validation and commercialization, to repositioning clinical stage compounds and identifying new indications for existing drugs.
Through our alliances, we are able to create new intellectual property and provide the basis for developing companion diagnostics. We are also leveraging our CSP platform to acquire and create new intellectual property around the development of select existing compounds.
Drive translational research to FIM through novel in-silico and in-vivo modeling
Enable clear segmentation of patients via subtyping during early drug development
Confirm subtype profilers as response biomarkers supporting accelerated drug, and companion diagnostic, development
Expand subtypes drug-response biomarkers in confirmatory and indication expansion studies to maximize market potential
Reposition and repurpose drugs by subtyping patients to reveal new or additional drug responder populations and commercial potential
GeneCentric has built its Cancer Subtyping Platform (CSP) by complementing our own internal expertise with a growing network of leading researchers, their research laboratories, and corresponding academic institutions. GeneCentric works with researchers and institutions to identify and advance the most promising, novel science relating to cancer and immune biology that lead to a greater understanding of disease development and expression.
By working with our collaborations, GeneCentric drives to translate these discoveries into breakthroughs that enable treatments for the most common and complex cancers. Our current collaborations are in the areas of cancer genomics and genetics, informatics, and numerous types of cancer.
GeneCentric partners with pharmaceutical and biotechnology companies in order to support the development of their pre-clinical, early and late-stage, as well as commercially available therapeutic programs and platforms. Through our CSP® platform of cancer profilers, GeneCentric supports the full spectrum of drug development.
Beginning with in-silico and in-vivo (PDX or other) models, we are able to rapidly undertake pre-clinical validation of cancer subtypes for specific drug candidates/targets. Next, from first in man (FIM) or early-stage trials, to validation/mid-stage clinical studies, to late-stage or regulatory-submission trials, CSP® profilers enables patient stratification/optimization and transfer readily to companion diagnostics to achieve rapid and successful drug/diagnostic development. GeneCentric is dedicated to speeding drug development and increasing the rate of program success at each stage of the process.